ABBV-CLS-484
Phase 1Small molecule
ABBV-CLS-484 is one of 4 small molecule programs targeting Metastatic Tumors. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Metastatic Tumors
#DrugCompanyPhaseTrials
1Immunotherapy
Bristol-Myers SquibbPhase 3
Hormones
DDavid Palma
Phase 3
BAT1006
BBio-Thera Solutions
Phase 2
ABBV-CLS-484
CCalico Life Sciences LLC
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ABBV-CLS-484. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCalico Life Sciences LLC